Skip to main content
Top

Diabetologia

Issue 12/1999

Content (17 Articles)

Editorial

The EASD at the crossroads

P. J. Lefebvre

Review

Endothelin: emerging role in diabetic vascular complications

R. L. Hopfner, V. Gopalakrishnan

Article

An aldose redutase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs

Y. Kasuya, M. Ito, J. Nakamura, Y. Hamada, M. Nakayama, S. Chaya, T. Komori, K. Naruse, E. Nakashima, K. Kato, N. Koh, N. Hotta

Short communication

Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration

A. Holzäpfel, A. Festa, G. Stacher-Janotta, H. Bergmann, N. Shnawa, W. Brannath, G. Schernthaner, G. Stacher

Short communication

Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells

Y. Kajimoto, T. Matsuoka, H. Kaneto, H. Watada, Y. Fujitani, M. Kishimoto, K. Sakamoto, M. Matsuhisa, R. Kawamori, Y. Yamasaki, M. Hori

Short communication

Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes

P. Ebeling, A. -M. Teppo, H. A. Koistinen, J. Viikari, T. Rönnemaa, M. Nissén, S. Bergkulla, P. Salmela, J. Saltevo, V. A. Koivisto

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine